Jesse's Journey Foundation

Defeat Duchenne. Change Lives.

News & Resources

PTC Study 041 Canadian trial sites

PTC Therapeutics has announced three Canadian sites for their clinical trial known as Study 041 for Duchenne muscular dystrophy.  Study 041 is looking at how the investigational treatment, ataluren, affects ability to walk and endurance in males aged five years and older with nmDMD, compared to placebo. More information about the study can be found by clicking here […]

Rick Moss Appointed to the CORD Board of Directors

I am very happy to share with you today the news that Rick Moss, our Director of Advocacy and Partnerships, has joined the Board of Directors of the Canadian Organization for Rare Disorders (CORD). Over the past two years Rick has been working diligently on behalf of Jesse’s Journey in the area of advocacy with […]

15th annual Tory’s Tourney

Last weekend was the 15th annual Tory’s Tourney for Jesse’s Journey, hosted by the Provenzano family in Windsor. It was another sold-out tournament – over the last 15 years, this amazing event has raised more than $400,000 for Duchenne muscular dystrophy research. And they’ve never been rained out! (knock on wood). Representing Jesse’s Journey were […]

First Patient Enrolled in Phase 2 Trial of MNK-1411, Mallinckrodt’s Investigational Therapy for DMD

The first patient has been enrolled in a Phase 2 trial evaluating the effectiveness and safety of MNK-1411, an investigational therapy for Duchenne muscular dystrophy (DMD), announced Mallinckrodt Pharmaceuticals, the treatment’s developer. The company also reported that MNK-1411 was granted orphan medicinal product status by the European Medicines Agency, facilitating the development and eventually the approval process for the treatment candidate. The therapy was given orphan drug designation in […]

A Note from John Davidson, August 9th

20-years-ago-today was my 122nd day on the road and I had reached London, my home town. It had been four months since I dipped the toes of my running shoes in the cold water of the Atlantic Ocean in St. John’s, Newfoundland and set out to walk across Canada at the age of 52. There’s […]

A protein could be key to preserving heart function in Duchenne muscular dystrophy

SAN ANTONIO, TEXAS, Aug. 1, 2018 — A protein known to drive nerve cell survival in the brain and spinal cord might also protect failing hearts in children and young adults with Duchenne muscular dystrophy, according to preliminary research presented at the American Heart Association’s Basic Cardiovascular Sciences Scientific Sessions, a premier global exchange of […]

FDA Places Hold on Phase 1/2 Trial of Sarepta’s Gene Therapy for DMD

A Phase 1/2 trial evaluating Sarepta’s microdystrophin gene therapy candidate for Duchenne muscular dystrophy (DMD) was placed on clinical hold by the U.S. Food and Drug Administration. The FDA found trace amounts of plasmid DNA in the raw material used to make the drug. The fragments don’t seem harmful in preliminary tests and the dosing of patients by the end of […]

Consortium.AI to Advance New Treatments for Duchenne Using Artificial Intelligence

Insilico Medicine and A2A Pharmaceuticals, two leading artificial intelligence (AI) biotechs, are collaborating to create a new company called Consortium.AI, which will advance AI for the development of new molecules to treat Duchenne muscular dystrophy (DMD) and other orphan diseases. Consortium.AI will feature computational new candidates designed to target specific diseases that were validated through Insilico’s AI systems. A2A Pharmaceuticals […]

4 Approaches to Treating Duchenne Muscular Dystrophy Highlighted at PPMD Conference

Discussions of the work being done on four different approaches to treating Duchenne muscular dystrophy (DMD) — repairing or replacing dystrophin, managing inflammation, improving muscle mechanics, and editing dysfunctional genes using CRISPR/CAS9 — were a highlight of sessions at the recent 2018 Parent Project Muscular Dystrophy (PPMD) conference in Scottsdale, Arizona. Patients, parents, doctors, researchers, and industry executives […]

Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.